Panel-based and hotspot testing may miss genomic variants—some of which may be actionable1,2
Allows the identification of transcript variants and fusions that may be undetectable through conventional CGP tests, which only employ DNA analysis3
*Whole-transcriptome with select variants reported in New York State
Understand the impact the test has on patients
Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®.‡
‡ OncoExtra was previously known as GEM ExTra.
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
GEM ExTra, OncoExTra; TMB, tumor mutational burden.
Detect more variants:
The OncoExTra test delivers the complete genomic story
Utilize patient-matched tumor-normal sequencing to further refine therapy selection
- Limit false positives by identifying and ruling out benign variants in a patient’s tumor sample vs normal blood sample3
- Reduce the overestimation of tumor mutational burden (TMB) calculations by excluding mutations also found in the normal sample3,4
Proven to reveal more clinically actionable information3
Actionable variants were found across many different types of solid tumors3